NASDAQ:SCYXSCYNEXIS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SCYNEXIS Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.05 -0.04 (-0.56 %) (As of 08/6/2020 03:46 PM ET) Add Compare Share Today's Range$6.99Now: $7.05▼$7.2050-Day Range$6.29MA: $7.20▼$8.2452-Week Range$5.00Now: $7.05▼$14.40Volume1,121 shsAverage Volume114,133 shsMarket Capitalization$69.65 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.00, SCYNEXIS has a potential upside of 555.3% from its current price of $7.02.Amount of Analyst CoverageSCYNEXIS has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesSCYNEXIS has received 471 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSCYNEXIS has received 383 “underperform” votes. (Add your “underperform” vote.)Community SentimentSCYNEXIS has received 55.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote “Outperform” if you believe SCYX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.06% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions37.12% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to grow in the coming year, from ($4.15) to ($2.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCYX Previous Symbol CUSIPN/A CIK1178253 Webwww.scynexis.com Phone201-884-5485Debt Debt-to-Equity Ratio2.23 Current Ratio5.22 Quick Ratio5.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120,000.00 Price / Sales580.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book5.34Profitability EPS (Most Recent Fiscal Year)($8.10) Net Income$-53,710,000.00 Net MarginsN/A Return on Equity-492.24% Return on Assets-101.81%Miscellaneous Employees27 Outstanding Shares9,880,000Market Cap$69.65 million Next Earnings DateN/A OptionableOptionable $7.05 -0.04 (-0.56 %) (As of 08/6/2020 03:46 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SCYX News and Ratings via Email Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)? SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SCYX stock has decreased by 9.6% and is now trading at $7.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of SCYNEXIS? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SCYNEXIS. How were SCYNEXIS's earnings last quarter? SCYNEXIS Inc (NASDAQ:SCYX) announced its earnings results on Monday, May, 11th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($1.50) by $0.80. View SCYNEXIS's earnings history. When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work? SCYNEXIS shares reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for SCYX? 6 brokers have issued 1 year target prices for SCYNEXIS's stock. Their forecasts range from $35.00 to $60.00. On average, they anticipate SCYNEXIS's share price to reach $46.00 in the next twelve months. This suggests a possible upside of 552.5% from the stock's current price. View analysts' price targets for SCYNEXIS. Has SCYNEXIS been receiving favorable news coverage? News articles about SCYX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SCYNEXIS earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about SCYNEXIS. Are investors shorting SCYNEXIS? SCYNEXIS saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 1,420,000 shares, a drop of 13.4% from the July 15th total of 1,640,000 shares. Based on an average trading volume of 105,200 shares, the days-to-cover ratio is currently 13.5 days. Approximately 15.4% of the shares of the stock are short sold. View SCYNEXIS's Current Options Chain. Who are some of SCYNEXIS's key competitors? Some companies that are related to SCYNEXIS include Magenta Therapeutics (MGTA), Osmotica Pharmaceuticals (OSMT), Immunic (IMUX), Ritter Pharmaceuticals (RTTR), REDHILL BIOPHAR/S (RDHL), Concert Pharmaceuticals (CNCE), NextCure (NXTC), Spero Therapeutics (SPRO), ProQR Therapeutics (PRQR), Urovant Sciences (UROV), Lannett (LCI), Northwest Biotherapeutics (NWBO), Fortress Biotech (FBIO), Verastem (VSTM) and Abeona Therapeutics (ABEO). View all competitors. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Cerus (CERS), Novavax (NVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Matinas BioPharma (MTNB), Verastem (VSTM), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX), Trevena (TRVN) and T2 Biosystems (TTOO). Who are SCYNEXIS's key executives? SCYNEXIS's management team includes the following people: Dr. Marco Taglietti, CEO, Pres & Director (Age 60, Pay $937.35k)Mr. Eric Francois, Chief Financial Officer (Age 45, Pay $604.91k)Mr. David Gonzalez Angulo, Chief Medical Officer (Age 55, Pay $676.13k)Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 42) What is SCYNEXIS's stock symbol? SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX." Who are SCYNEXIS's major shareholders? SCYNEXIS's stock is owned by many different retail and institutional investors. Top institutional investors include Creative Planning (2.10%). Company insiders that own SCYNEXIS stock include Gonzalez David Angulo and Marco Taglietti. View institutional ownership trends for SCYNEXIS. Which major investors are buying SCYNEXIS stock? SCYX stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought SCYNEXIS stock in the last two years include Gonzalez David Angulo, and Marco Taglietti. View insider buying and selling activity for SCYNEXIS. How do I buy shares of SCYNEXIS? Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is SCYNEXIS's stock price today? One share of SCYX stock can currently be purchased for approximately $7.05. How big of a company is SCYNEXIS? SCYNEXIS has a market capitalization of $69.65 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis. SCYNEXIS employs 27 workers across the globe. What is SCYNEXIS's official website? The official website for SCYNEXIS is www.scynexis.com. How can I contact SCYNEXIS? SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
